Channel Therapeutics Corp. Files 2024 10-K
Ticker: PTHS · Form: 10-K · Filed: 2025-03-27T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, biotech
TL;DR
Channel Therapeutics filed its 2024 10-K. All systems go.
AI Summary
Channel Therapeutics Corp. filed its 2024 10-K on March 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, formerly Chromocell Therapeutics Corp., is incorporated in Nevada and operates in the biological products sector. Its principal business address is in North Brunswick, NJ.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Channel Therapeutics Corp.'s financial health, operational performance, and strategic direction for the fiscal year 2024.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific risk factors or financial performance details that would indicate a high-risk level.
Key Numbers
- 7955338 — Total Assets (Reported for fiscal year 2024)
- 513443 — Total Liabilities (Reported for fiscal year 2024)
- 7955338 — Total Equity (Reported for fiscal year 2024)
Key Players & Entities
- Channel Therapeutics Corp. (company) — Filer of the 10-K
- Chromocell Therapeutics Corp. (company) — Former name of Channel Therapeutics Corp.
- 2024-12-31 (date) — Fiscal year end
- 2025-03-27 (date) — Filing date
- North Brunswick, NJ (location) — Business and mailing address
FAQ
What is the primary business of Channel Therapeutics Corp.?
Channel Therapeutics Corp. operates in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
When did Channel Therapeutics Corp. change its name from Chromocell Therapeutics Corp.?
The company changed its name from Chromocell Therapeutics Corp. on March 23, 2022.
What is the fiscal year end for Channel Therapeutics Corp.?
The fiscal year end for Channel Therapeutics Corp. is December 31.
What is the filing date of this 10-K report?
This 10-K report was filed on March 27, 2025.
Where is Channel Therapeutics Corp. located?
Channel Therapeutics Corp.'s business and mailing address is 685 US Highway One, North Brunswick, NJ 08902.
From the Filing
0001753926-25-000503.txt : 20250327 0001753926-25-000503.hdr.sgml : 20250327 20250327170842 ACCESSION NUMBER: 0001753926-25-000503 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250327 DATE AS OF CHANGE: 20250327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Channel Therapeutics Corp CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 25780409 BUSINESS ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 BUSINESS PHONE: 9176446313 MAIL ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 10-K 1 g084720_10k.htm 10-K false 2024 FY --12-31 0001919246 7955338 513443 7955338 513443 7955338 513443 96391 6103813 1.30 P10Y P10Y P9Y0M29D P10Y P9Y4M24D P8Y10M14D P9Y9M3D P10Y P9Y3M26D P9Y2M12D P2Y0M4D P4Y10M17D P4Y4M17D P4Y4M17D 0001919246 2024-01-01 2024-12-31 0001919246 2024-06-28 0001919246 2025-03-26 0001919246 2024-12-31 0001919246 2023-12-31 0001919246 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001919246 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001919246 us-gaap:SeriesCPreferredStockMember 2024-12-31 0001919246 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001919246 2023-01-01 2023-12-31 0001919246 chro:SeriesAPreferredSharesMember 2022-12-31 0001919246 chro:SeriesCPreferredSharesMember 2022-12-31 0001919246 us-gaap:CommonStockMember 2022-12-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001919246 us-gaap:RetainedEarningsMember 2022-12-31 0001919246 2022-12-31 0001919246 chro:SeriesAPreferredSharesMember 2023-12-31 0001919246 chro:SeriesCPreferredSharesMember 2023-12-31 0001919246 us-gaap:CommonStockMember 2023-12-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001919246 us-gaap:RetainedEarningsMember 2023-12-31 0001919246 chro:SeriesAPreferredSharesMember 2023-01-01 2023-12-31 0001919246 chro:SeriesCPreferredSharesMember 2023-01-01 2023-12-31 0001919246 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001919246 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001919246 chro:SeriesAPreferredSharesMember 2024-01-01 2024-12-31 0001919246 chro:SeriesCPreferredSharesMember 2024-01-01 2024-12-31 0001919246 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001919246 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001919246 chro:SeriesAPreferredSharesMember 2024-12-31 0001919246 chro:SeriesCPreferredSharesMember 2024-12-31 0001919246 us-gaap:CommonStockMember 2024-12-31 0001919246 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001919246 us-gaap:RetainedEarningsMember 2024-12-31 0001919246 chro:ConsultantMember 2024-01-01 2024-12-31 0001919246 chro:ConsultantMember 2023-01-01 2023-12-31 0001919246 chro:LabGasMember 2024-01-01 2024-12-31 0001919246 chro:LabGasMember 2023-01-01 2023-12-31 0001919246 chro:LabCellStorageMember 2024-01-01 2024-12-31 0001919246 chro:LabCellStorageMember 2023-01-01 2023-12-31 0001919246 chro:ChemistryManufacturingAndControlsMember 2024-01-01 2024-12-31 0001919246 chro:ChemistryManufacturingAndControlsMember 2023-01-01 2023-12-31 0001919246 chro:IPServicesMember 2024-01-01 2024-12-31 0001919246 chro:IPServicesMember 2023-01-01 2023-12-31 0001919246 chro:StockOptionsMember 2024-01-01 2024-12-31 0001919246 chro:WarrantsMember 2024-01-01 2024-12-31 0001919246 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001919246 chro:StockOptionsMember 2023-01-01 2023-12-31 0001919246 chro:EmploymentAgreementMember 2024-02-13 2024-02-14 0001919246 ch